

News Release

August 14, 2008

Notice of Acquisition of Treasury Stock through ToSTNeT-3

Japan, August 14, 2008 --- Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori; hereinafter called "the Company") announced today that it has decided the specific method of acquisition of treasury stock pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Method of acquisition:

Shares will be purchased at the Tokyo Stock Exchange at 8:45am on August 15, 2008 by a closing price of \(\frac{\pmathbf{4}}{4},800\) per share as of today, August 14, 2008. Transactions will be made through ToSTNeT-3 and shall neither be made by other trading systems nor at another time. The purchase order will be valid only at the time designated for transactions.

2. Contents of acquisition:

- Class of shares to be acquired: Common stock of the Company

- Total number of shares to be acquired: 5.5 million shares

Note 1) The number of shares will not be changed. Depending on market fluctuations and other factors, a part or all of these shares may not be acquired.

Note 2) The purchase is to be made in response to sell orders corresponding to the number of shares planned to be acquired.

3. Announcement of the result:

The result of acquisition will be announced after the time designated for transactions at 8:45am on August 15, 2008.

(Reference)

Details of the resolution at the meeting of the Board of Directors (announced on August 1, 2008)

Class of shares to be acquired:
 Number of shares to be acquired:
 Aggregate amount of acquisition cost:
 Y 50 billion (maximum)

The status of the acquisition progress as of August 14, 2008
- Number of shares acquired: 3,868,900 shares
- Accumulated acquisition cost: ¥ 18,997,955,000

######

Contacts for inquiries or additional information

Astellas Pharma Inc.

Corporate Communications

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

http://www.astellas.com